D. E. Shaw & Co., Inc. Incyte Corp Put Options Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $899,428 - $1.05 Million	-14,200 Reduced 78.89%	3,800 $279,000
Q1 2020 May 15, 2020	BUY	$63.18 - $85.97 $499,122 - $679,163	7,900 Added 78.22%	18,000 $1.32 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $7.5 Million - $10.4 Million	-118,000 Reduced 92.12%	10,100 $869,000
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $926,250 - $1.11 Million	-15,000 Reduced 10.48%	128,100 $8.85 Million
Q2 2018 Aug 14, 2018	BUY	$60.85 - $83.98 $1.52 Million - $2.1 Million	25,000 Added 21.17%	143,100 $9.59 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $7.01 Million - $8.52 Million	84,400 Added 250.45%	118,100 $9.84 Million
Q4 2017 Feb 14, 2018	BUY	$93.56 - $116.6 $2.22 Million - $2.76 Million	23,700 Added 237.0%	33,700 $3.19 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $1.09 Million - $1.38 Million	10,000	10,000 $1.17 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.